enGene Therapeutics (ENGN) Income from Continuing Operations (2023 - 2026)
enGene Therapeutics (ENGN) posted quarterly Income from Continuing Operations of 30227000.0 for Q2 2026, down 17.09% year-over-year from 36457973.41 in Q2 2025, and down 1.6% quarter-over-quarter from 29752000.0 in Q1 2026.
enGene Therapeutics (ENGN) Income from Continuing Operations (2023 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported Income from Continuing Operations for 4 consecutive years, with 30227000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Income from Continuing Operations fell 17.09% year-over-year to 30227000.0; the TTM figure through Apr 2026 stood at 23123000.0 (up 71.05% YoY), while the FY2025 annual figure was 13575000.0, up 75.38% from the prior year.
- Income from Continuing Operations eased to 30227000.0 in Q2 2026 per ENGN's latest filing, from 29752000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 65847000.0 in Q4 2025 and bottomed at 82497000.0 in Q4 2023.
- Historically, Income from Continuing Operations has averaged 16329500.0 across 4 years, with a median of 15141500.0 in 2024.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations sank 199.75% — and 2025, when it jumped 530.4%.
- enGene Therapeutics' Income from Continuing Operations stood at 82497000.0 in 2023, then surged by 81.46% to 15299000.0 in 2024, then surged by 530.4% to 65847000.0 in 2025, then tumbled by 145.9% to 30227000.0 in 2026.
- Business Quant data shows ENGN's Income from Continuing Operations at 30227000.0 in Q2 2026, 29752000.0 in Q1 2026, and 65847000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | enGene Therapeutics | 124.11 Mn | 124.11 Mn | - | -30.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -30.23 Mn |
| Jan 31, 2026 | -29.75 Mn |
| Oct 31, 2025 | 65.85 Mn |
| Jul 31, 2025 | -28.99 Mn |
| Apr 30, 2025 | -25.82 Mn |
| Jan 31, 2025 | -24.62 Mn |
| Oct 31, 2024 | -15.30 Mn |
| Jul 31, 2024 | -14.15 Mn |
| Apr 30, 2024 | -14.98 Mn |
| Jan 31, 2024 | -10.71 Mn |
| Oct 31, 2023 | -82.50 Mn |
| Jul 31, 2023 | -4.72 Mn |
| Apr 30, 2023 | -5.28 Mn |
| Jan 31, 2023 | -7.42 Mn |